Development and Validation of a Diagnostic Model for AKI Based on the Analysis of Ferroptosis-related Genes.

IF 3.5 4区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current medicinal chemistry Pub Date : 2024-11-21 DOI:10.2174/0109298673296300240829075534

Hengyue Zhu, Xuejia Yang, Ziwei Yuan, Zujian Hu, Yangyang Guo, Yongheng Bai, Jingzong Zhou

{"title":"Development and Validation of a Diagnostic Model for AKI Based on the Analysis of Ferroptosis-related Genes.","authors":"Hengyue Zhu, Xuejia Yang, Ziwei Yuan, Zujian Hu, Yangyang Guo, Yongheng Bai, Jingzong Zhou","doi":"10.2174/0109298673296300240829075534","DOIUrl":null,"url":null,"abstract":"Background: Acute kidney injury (AKI) is a common renal condition associated with various factors, including pre-renal, post-renal, and renal causes, with ischemia- reperfusion being a frequent contributor leading to tubular injury. Early identification of AKI is crucial but remains challenging.Methods: This study explored the molecular signature of AKI using gene microarray data from the GEO dataset, focusing on identifying ferroptosis-related features through three machine-learning algorithms. We also validated potential biomarkers through a hypoxia/ reoxygenation model.Results: ROC curves, expression differences, and associations with immune cells were analyzed for the three markers to confirm their potential as AKI biomarkers, each demonstrating strong diagnostic ability. Combining these markers proved more effective.Conclusion: The combination of AEBP2, MDM2, and NR4A1 as diagnostic biomarkers for AKI not only enhances detection capability but also holds promise as a significant tool in clinical practice, providing patients with diagnostic and therapeutic guidance.","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673296300240829075534","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute kidney injury (AKI) is a common renal condition associated with various factors, including pre-renal, post-renal, and renal causes, with ischemia- reperfusion being a frequent contributor leading to tubular injury. Early identification of AKI is crucial but remains challenging.

Methods: This study explored the molecular signature of AKI using gene microarray data from the GEO dataset, focusing on identifying ferroptosis-related features through three machine-learning algorithms. We also validated potential biomarkers through a hypoxia/ reoxygenation model.

Results: ROC curves, expression differences, and associations with immune cells were analyzed for the three markers to confirm their potential as AKI biomarkers, each demonstrating strong diagnostic ability. Combining these markers proved more effective.

Conclusion: The combination of AEBP2, MDM2, and NR4A1 as diagnostic biomarkers for AKI not only enhances detection capability but also holds promise as a significant tool in clinical practice, providing patients with diagnostic and therapeutic guidance.

查看原文本刊更多论文

基于铁突变相关基因分析的 AKI 诊断模型的开发与验证

背景：急性肾损伤（AKI）是一种常见的肾脏疾病，与多种因素有关，包括肾前、肾后和肾脏原因，其中缺血再灌注是导致肾小管损伤的常见因素。早期识别 AKI 至关重要，但仍具有挑战性：本研究利用 GEO 数据集中的基因芯片数据探索了 AKI 的分子特征，重点是通过三种机器学习算法识别与铁突变相关的特征。我们还通过缺氧/再氧模型验证了潜在的生物标志物：结果：我们对三种标记物的ROC曲线、表达差异以及与免疫细胞的关联进行了分析，确认了它们作为AKI生物标记物的潜力，每种标记物都表现出很强的诊断能力。结论：将 AEBP2、MDM2 和 NR4A1 结合起来作为 AKI 的诊断生物标志物不仅能提高检测能力，而且有望成为临床实践中的重要工具，为患者提供诊断和治疗指导。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current medicinal chemistry 医学-生化与分子生物学

CiteScore

8.60

自引率

2.40%

发文量

468

审稿时长

3 months

期刊介绍： Aims & Scope Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.